Novartis tests Inflammation-Fighting drugs for High-Risk heart patients
NCT ID NCT06097663
Summary
This study tested whether two experimental drugs, DFV890 (a daily pill) and MAS825 (a single injection), could safely reduce specific markers of inflammation in the blood. It involved about 31 adults who had both coronary heart disease and a specific genetic blood condition called CHIP. The goal was to see if lowering these inflammation markers could potentially help control future heart disease risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Montreal, Quebec, H1T 1C8, Canada
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Bonn, 53105, Germany
-
Novartis Investigative Site
München, 80636, Germany
-
Vanderbilt University Medical Cent
Nashville, Tennessee, 37232-8805, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.